Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

Oriol Iborra-Egea, Evelyn Santiago-Vacas, Salva R Yurista, Josep Lupón, Milton Packer, Stephane Heymans, Faiez Zannad, Javed Butler, Domingo Pascual-Figal, Antonio Lax, Julio Núñez, Rudolf A de Boer, Antoni Bayés-Genís

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The mechanism of action of empagliflozin in heart failure with reduced ejection fraction (HFrEF) was deciphered using deep learning in silico analyses together with in vivo validation. The most robust mechanism of action involved the sodium-hydrogen exchanger (NHE)-1 co-transporter with 94.7% accuracy, which was similar for diabetics and nondiabetics. Notably, direct NHE1 blockade by empagliflozin ameliorated cardiomyocyte cell death by restoring expression of X-linked inhibitor of apoptosis (XIAP) and baculoviral IAP repeat-containing protein 5 (BIRC5). These results were independent of diabetes mellitus comorbidity, suggesting that empagliflozin may emerge as a new treatment in HFrEF.

Original languageEnglish
Pages (from-to)831-840
Number of pages10
JournalJACC: Basic to Translational Science
Volume4
Issue number7
DOIs
Publication statusPublished - Nov 2019

Cite this